Do B vitamins that lower homocysteine protect your heart and brain?

Every time your body processes methionine, it produces homocysteine as an intermediate. Healthy metabolism then channels homocysteine down one of two pathways: it is either converted to cysteine (requiring vitamin B6) or remethylated back to methionine (requiring folate and vitamin B12). When either of these routes is slowed — by B vitamin deficiency, by the MTHFR genetic variant, by kidney disease, or by certain medications — homocysteine accumulates in the blood.

The enzyme MTHFR (methylenetetrahydrofolate reductase) is central to this process. Around 10–15% of people carry a variant that reduces MTHFR activity by 40–70%, increasing their reliance on dietary folate and making them more prone to elevated homocysteine. See our Folate and MTHFR page for detail on how the form of folate you eat matters.

Why Elevated Homocysteine Is Harmful

High homocysteine injures the endothelium — the thin inner lining of every blood vessel in your body. The mechanisms include:

• Oxidative stress — homocysteine generates reactive oxygen species that damage cell membranes and oxidize LDL cholesterol
• Reduced nitric oxide — less NO means blood vessels cannot dilate properly, raising blood pressure
• Inflammation — homocysteine activates inflammatory pathways within vessel walls
• Abnormal clotting — it promotes platelet aggregation and reduces the body's ability to break down clots

Over time, this creates fertile ground for atherosclerosis, coronary artery disease, peripheral artery disease, and stroke. In the brain, homocysteine is directly neurotoxic, promoting grey matter atrophy and impairing neurotransmitter pathways that depend on methylation.

What Level Is Concerning?

Most labs flag homocysteine as abnormal only above 15 µmol/L, but the research evidence suggests risk increases well below that threshold:

• Optimal: below 7–10 µmol/L
• Borderline elevated: 10–15 µmol/L
• High: 15–30 µmol/L
• Severe (homocystinuria): above 30 µmol/L

A 5 µmol/L increase in homocysteine corresponds to roughly a 50% increase in CHD mortality risk in prospective studies².

Lowering Homocysteine Through Diet and Supplements

Folate is the single most important dietary factor. Dark leafy greens (spinach, kale, arugula), legumes, and asparagus are the richest sources. For those with MTHFR variants, getting adequate methylfolate — whether from food or from supplemental methyltetrahydrofolate — is more effective than folic acid. Even in people with apparently normal folate status, increasing intake typically lowers homocysteine.

Vitamin B12 works synergistically with folate in the remethylation pathway. People eating plant-based diets are at particular risk of B12 deficiency and elevated homocysteine. Rich food sources include meat, fish, shellfish, and eggs. Sublingual methylcobalamin or cyanocobalamin supplements are effective.

Vitamin B6 supports the alternative pathway that converts homocysteine to cysteine. Poultry, fish, potatoes, and bananas are good sources.

Betaine (trimethylglycine) found in beets, spinach, and quinoa donates methyl groups directly to the remethylation pathway, independently of folate. It can be useful when folate is already adequate but homocysteine remains elevated.

If blood tests confirm elevated homocysteine, a common supplement protocol is: methylfolate 400–800 mcg, methylcobalamin B12 500–1000 mcg, and B6 (as pyridoxine or P5P) 10–25 mg daily. Levels typically respond within 4–8 weeks.

Other contributors to watch

• Kidney disease — the kidneys help excrete homocysteine; renal impairment raises levels
• Medications — metformin (reduces B12 absorption), methotrexate (folate antagonist), proton pump inhibitors, and nitrous oxide all elevate homocysteine
• Hypothyroidism — impairs homocysteine metabolism
• Heavy coffee consumption — modest independent effect
• Smoking — lowers folate and raises homocysteine

Who Should Get Tested?

Homocysteine testing is a standard fasting blood draw but is not included in routine panels. It is worth requesting if you have a family history of early heart disease or stroke, if you are eating a plant-heavy or vegan diet, if you are over 60, or if you have any concerns about cognitive decline. Functional medicine practitioners routinely include it in cardiovascular and longevity panels. Related tests that pair well include: serum folate, serum B12, complete blood count, and methylmalonic acid (a sensitive marker of functional B12 status).

See our Betaine page and Choline page for more on the methylation network that keeps homocysteine in check.

Epidemiological link with cardiovascular disease

The association between homocysteine and cardiovascular disease rests on a large body of prospective observational data. Boushey et al. (1995) published a landmark meta-analysis in JAMA compiling 27 studies and found that each 5 µmol/L increment in plasma homocysteine conferred roughly 60–80% higher coronary artery disease risk in men and 70% higher risk in women — a magnitude comparable in scale to hypercholesterolemia and smoking¹. This analysis also estimated that raising average folic acid intake could prevent 10% or more of coronary deaths annually in the US population.

Peng et al. (2015) updated this picture with a meta-analysis of 12 prospective studies totalling 23,623 subjects². Per 5 µmol/L homocysteine increment, pooled risk ratios were 1.52 for coronary heart disease mortality, 1.32 for cardiovascular mortality, and 1.27 for all-cause mortality. Comparing the highest versus lowest homocysteine categories, CHD mortality was 66% higher, cardiovascular mortality 68% higher, and all-cause mortality 93% higher — with stronger effects seen in elderly populations. The study was well-controlled for conventional risk factors including LDL, blood pressure, and diabetes, suggesting homocysteine carries independent predictive value.

Brain atrophy and cognitive decline

The VITACOG trial is the strongest randomized evidence linking homocysteine to brain aging. Smith et al. (2010) enrolled 271 adults over 70 with mild cognitive impairment (MCI) and randomized them to daily high-dose B vitamins (0.8 mg folic acid, 0.5 mg vitamin B12, 20 mg vitamin B6) or placebo for 2 years³. Serial MRI measurements showed a mean brain atrophy rate of 0.76%/year in the treatment group versus 1.08%/year in placebo (p = 0.001) — a 30% slowing. The benefit was greatest among participants with baseline homocysteine above the median (11.3 µmol/L), suggesting that elevated homocysteine is part of the causal pathway rather than merely a marker.

A follow-up analysis by de Jager et al. (2012) examined cognitive outcomes from the same trial⁴. B vitamin treatment produced significant improvements in global cognition (MMSE), episodic memory (HVLT-R), and semantic memory over the 2-year period compared to placebo, particularly in participants with the highest baseline homocysteine. The cognitive and brain atrophy benefits aligned, reinforcing the mechanistic interpretation.

Jernerén et al. (2015) identified an important interaction: in a post-hoc analysis of the 168 VITACOG participants who had MRI scans, B vitamins slowed brain atrophy (by 40.0% compared with placebo) only in participants with high baseline omega-3 fatty acid status (combined EPA and DHA above 590 µmol/L)⁷. In those with low omega-3s (below 390 µmol/L), B vitamins had no significant effect on atrophy. The authors also suggested that the beneficial effect of omega-3 fatty acids on brain atrophy may be confined to people with good B vitamin status. A separate analysis of the same trial, by Oulhaj et al. (2016), found the same pattern for cognition: when omega-3 concentrations were low, B vitamin treatment had no effect on cognitive decline in MCI, but when omega-3 levels were in the upper normal range, B vitamins interacted to slow cognitive decline⁵. This interaction has practical implications: optimizing both B vitamins and omega-3 status may be necessary for cognitive protection. Sample sizes in the stratified analysis were modest, so this finding warrants replication.

B vitamin supplementation and cardiovascular outcomes

Huang et al. (2012) pooled 19 randomized trials (47,921 participants) examining B vitamin supplementation on cardiovascular outcomes⁶. B vitamins produced a statistically significant reduction in stroke risk (RR 0.88, 95% CI 0.82–0.95) but did not significantly reduce myocardial infarction, overall CVD events, or all-cause mortality. Blood homocysteine levels were decreased in all of the included trials, yet the authors found a protective effect only on stroke, and none on cardiovascular disease overall, coronary heart disease, myocardial infarction, cardiovascular death, or all-cause mortality.

The cardiovascular evidence should be interpreted with appropriate nuance. Observational data strongly link homocysteine to cardiovascular events, but randomized trials lowering homocysteine via B vitamins have produced inconsistent cardiovascular event reductions. Several explanations have been proposed: folic acid fortification in many countries already corrected elevated homocysteine before trials enrolled; many participants in B-vitamin trials had normal or near-normal homocysteine at baseline; and the trials enrolled people with established cardiovascular disease where vascular damage may have been irreversible. For people with confirmed elevated levels — and especially for cognitive outcomes — the evidence for intervention is stronger than the mixed cardiovascular trial literature might suggest.